📰 2 sources covering this story

STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more

First covered 14 hrs ago · latest take 6 mins ago. Compare how each outlet is covering it — and rate the sources you trust.

STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
STAT News
STAT News6 mins ago
STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
Eli Lilly confirmed that it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug
Reuters
Reuters🏁 first to report14 hrs ago
Eli Lilly to offer early access to next-gen obesity drug to some patients
Eli Lilly to offer early access to next-gen obesity drug to some patients  Reuters
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →